Business Context and Reporting Period
This Form 8-K was filed by Pavmed Inc. on January 30, 2024, reporting an event that occurred on January 26, 2024. The company is incorporated in Delaware and trades on The Nasdaq Stock Market under the symbols PAVM (Common Stock) and PAVMZ (Series Z Warrants).
Key Financial Metrics
This filing does not contain comprehensive financial statements, revenue, profit, cash flow, or margin data. The specific financial event reported involves a non-cash transaction:
- Transaction Value: $4,675,256 in fees and reimbursements.
- Counterparty: Lucid Diagnostics Inc., a majority-owned subsidiary of Pavmed Inc.
- Settlement Method: Issuance of 3,331,771 shares of Lucid Diagnostics common stock to Pavmed Inc.
Material Changes
The filing details a material change in the settlement of intercompany obligations. Instead of receiving cash, Pavmed Inc. elected to receive equity in its subsidiary, Lucid Diagnostics, to satisfy outstanding fees and reimbursements totaling approximately $4.68 million.
Guidance, Outlook, and Risks
The filing does not provide forward-looking guidance, management commentary on future operations, or specific risk factors beyond the disclosure of the transaction itself. The document references a separate Form 8-K filed by Lucid Diagnostics on January 30, 2024, for further details on the transaction.
Investor Verification Checklist
- Verify the impact of the $4.68 million non-cash settlement on Pavmed's consolidated balance sheet and cash flow position.
- Review the separate Form 8-K filed by Lucid Diagnostics on January 30, 2024, for detailed terms of the stock issuance.
- Assess the valuation of the 3,331,771 Lucid Diagnostics shares issued relative to the fee amount.
- Confirm the current ownership percentage of Lucid Diagnostics held by Pavmed Inc. following this transaction.